Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019

• Main Authors: Scott W. Canna (Author), Grant S. Schulert (Author), Adriana de Jesus (Author), Alex Pickering (Author), Hermine Brunner (Author), Massimo Gadina (Author), Stewart Levine (Author), Raphaela Goldbach-Mansky (Author), Jonathan Boutelle (Author), Rashmi Sinha (Author), Fabrizio DeBenedetti (Author), Alexei Grom (Author), on behalf of the NextGen 2019 Participants (Author)
• Format: Book
• Published: BMC, 2020-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Abstract For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3-4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation ( www.systemicjia.org/ ) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.

Item Description

10.1186/s12969-020-00444-7
1546-0096